SCHEMBL3925720

SCHEMBL3925720

O=S(=O)(Cc1cc(N2CCOCC2)nc(Cl)n1)c1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.66
MTOR P42345 13/20 0.66
PIK3CA P42336 12/20 0.66
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
PIK3CB P42338 3/20 0.47
PIK3CD O00329 2/20 0.47
AKT1 P31749 2/20 0.42
PIK3CG P48736 1/20 0.42
PRKDC P78527 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATR Q13535 2/20 0.41
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600075 0.88 MTOR (0.67) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL3928562 0.87 POLB (0.64) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL3597871 0.83 PIK3CA (0.50) POLBMTORPIK3CAPIK3CDPIK3C3
SCHEMBL1270683 0.80 POLB (1.00) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL1272440 0.79 MTOR (1.00) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL1271807 0.79 MTOR (0.65) POLBMTORPIK3CAPIK3CDPRKDC
SCHEMBL2489923 0.78 POLB (0.55) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL3923605 0.78 MTOR (0.59) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL2493247 0.77 POLB (0.51) POLBMTORPIK3CAALDH1A1KDM4E
SCHEMBL2487498 0.76 MTOR (0.62) POLBMTORPIK3CAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074118-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES AstraZeneca AB (SE) 2009-07-01 EP disclosed
US-20090018134-A1 Compounds - 945 ASTRAZENECA AB (SE) 2009-01-15 US disclosed
US-20090018134-A1 Compounds - 945 ASTRAZENECA AB (SE) 2009-01-15 US disclosed
US-20090018134-A1 Compounds - 945 ASTRAZENECA AB (SE) 2009-01-15 US disclosed
WO-2009007748-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018134-A1 Compounds - 945 MTOR, PIK3CA, PIK3R5 POLB 841/4885MTOR 1/4885PIK3CA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.